Greensboro, NC, United States of America

Douglas Hepler

This inventor holds 21 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Injectable Formulations. Top assignees: Dechra Veterinary Products, LLC, Piedmont Animal Health Inc., Bayer Healthcare LLC. Active years: 1990-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Douglas Hepler. Retrieved from https://idiyas.com/inventor/douglas-hepler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 14)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 11)

Average Co-Inventor Count = 3.5

ph-index = 5

Forward Citations = 90(Granted Patents)

Location History:

High Point, NC (US) (1990 - 2001)
McLeansville, NC (US) (1999 - 2017)
Greensboro, NC (US) (2019 - 2023)
Overland Park, KS (US) (2024)

Company Filing History:

6 out of 8

Dechra Veterinary Products, LLC

patents

6 out of 6

Piedmont Animal Health Inc.

Ciba-Geigy Corporation

patents

5. 2 out of 288

Idexx Laboratories, Inc.

patents

6. 2 out of 31

Novartis Animal Health US, Inc.

patents

7. 1 out of 2

Idexx Pharmaceuticals, Inc.

patents

Years Active: 1990-2025

Loading Chart...

Areas of Expertise:

Otic Formulations

Injectable Antibiotic Formulations

Long-acting Formulations

Acaricides

Insect Growth Regulators

Phospholipid-coated Microcrystals

Parasiticidal Agents

Liposomal Analgesics

Otitis Externa Treatment

Sustained Release

Parasite Control

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12491189 - OTIC formulations, methods and devices (2025-12-09),

2. 12357648 - Injectable antibiotic formulations and use thereof (2025-07-15),

3. 12350281 - Long-acting injectable formulations and use thereof (2025-07-08),

4. 12005071 - Injectable antibiotic formulations and use thereof (2024-06-11),

5. 11986483 - Otic formulations, methods and devices (2024-05-21),

6. 11628180 - Injectable antibiotic formulations and use thereof (2023-04-18),

7. 11375717 - Combinations of acaricides and insect growth regulators for control of fleas without emesis in animals (2022-07-05),

8. 11058629 - Long-acting non-aqueous injectable formulations and use thereof (2021-07-13),

9. 10736318 - Combinations of acaricides and insect growth regulators for control of fleas without emesis in animals (2020-08-11),

10. 10729709 - Injectable antibiotic formulations and use thereof (2020-08-04),

11. 10555899 - Long-acting non-aqueous injectable formulations and use thereof (2020-02-11),

12. 10286003 - Injectable antibiotic formulations and use thereof (2019-05-14),

13. 9820977 - Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent (2017-11-21),

14. 8927006 - Methods and compositions for rapid treatment of otitis externa (2015-01-06),

15. 6936273 - Liposomal analgesic formulation and use (2005-08-30),

Title: The Innovative Contributions of Douglas I Hepler

Introduction

Douglas I Hepler is a notable inventor based in McLeansville, NC (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of nine patents to his name, Hepler has made strides in developing treatments for various medical conditions, particularly those related to parasites and ear infections.

Latest Patents

Among his latest patents, Hepler has developed a systemic treatment for blood-sucking and blood-consuming parasites. This innovative approach involves the oral administration of a parasiticidal agent, specifically focusing on compositions of imidacloprid. These compositions are designed to control targeted parasites such as fleas, ticks, certain species of helminthes, and scabies. Additionally, Hepler has patented methods and compositions for the rapid treatment of otitis externa. This treatment method allows for the prevention and treatment of ear infections with a single dose, utilizing topical administration of lipid carrier compositions that are free from viscocity-enhancing celluloses or adhesives.

Career Highlights

Hepler has had a distinguished career, working with prominent companies such as IDEXX Laboratories, Inc. and Ciba-Geigy Corporation. His work in these organizations has contributed to the advancement of pharmaceutical innovations and the development of effective treatment solutions.

Collaborations

Hepler has collaborated with notable individuals in the field, including William R Campbell and Roland H Johnson. These partnerships have likely enhanced the scope and impact of his inventions.

Conclusion

Douglas I Hepler's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes through inventive solutions. His patents reflect a deep understanding of medical challenges and a dedication to finding effective treatments.

Profile summary based on public USPTO records.